Inhaled Well toleratedLow risk of adverse effects
Systemic Poorly toleratedHigh risk of adverse effects
Pulmocide develops inhaled medicines to target the site of disease in the lung with minimal systemic exposure
The small molecules accumulate in the lung for sustained treatment
We are developing novel, potent first-in-class anti-infective agents for delivery by inhaled administration for life-threatening lower respiratory infections.